Publications associées à Chimiothérapie

Recent Considerations in the Application of RAPTA-C for Cancer Treatment and Perspectives for Its Combination with Immunotherapies

Paul Joseph Dyson, Patrycja Nowak-Sliwinska, Magdalena Rausch

The organometallic ruthenium(II) [Ru(arene)Cl2PTA] PTA - 1,3,5-triaza-7-phosphaadamantane compound, RAPTA-C, represents an innovative anti-cancer therapeutic and a better-tolerated alternative to platinum (Pt)-based chemotherapeutic drugs in the treatment ...

WILEY2019

Lymphoma Chemotherapy: Hungry Macrophages Strike the Final Blow

Michele De Palma

Macrophages modulate tumor response to chemotherapy; in this issue, Lossos and colleagues show that high-dose alkylating agents instigate a synthetic lethal program in lymphoma cells that is independent of DNA damage and involves recruitment and priming of ...

AMER ASSOC CANCER RESEARCH2019

Type I interferon/IRF7 axis instigates chemotherapy-induced immunological dormancy in breast cancer

Mauro Delorenzi, Yu-Ting Huang

Neoadjuvant and adjuvant chemotherapies provide survival benefits to breast cancer patients, in particular in estrogen receptor negative (ER-) cancers, by reducing rates of recurrences. It is assumed that the benefits of (neo)adjuvant chemotherapy are due ...

Springer2019

Versatile Route to trans-Platinum(II) Complexes via Manipulation of a Coordinated 3-(Pyridin-3-yl)propanoicAcid Ligand

Paul Joseph Dyson, Tina Riedel, Marta Maroto Diaz

We describe the direct coupling of alcohols and amines to a 3-(pyridin-3-yl)propanoic acid ligand coordinated to a Pt(II) to afford ester and amide derivatives. Using this approach, a family of trans-Pt(II) compounds with amine ligands bearing long perfluo ...

2019

RasGRP1 is a potential biomarker for stratifying anti-EGFR therapy response in colorectal cancer

Mauro Delorenzi, Delphine Yvette L Grun

Colorectal cancer (CRC) is the third most frequent neoplastic disorder and is a main cause of tumor-related mortality, as many patients progress to stage IV metastatic CRC. Standard care consists of combination chemotherapy (FOLFIRI or FOLFOX). Patients wi ...

AMER SOC CLINICAL INVESTIGATION INC2019

Heterobimetallic Ru(mu-dppm)Fe and homobimetallic Ru(mu-dppm)Ru complexes as potential anti-cancer agents

Paul Joseph Dyson, Lucinda Kate Batchelor

Two heterobimetallic mu-dppm bridged Fe,Ru complexes, [(eta(6)-Arene)RuCl2(mu-dppm)Fe(CO)I(eta(5)-C5H5)] (Ar - C6H6 (1) and p-cymene (2), dppm-1,1-bis(diphenylphosphino)methane) were obtained in a facile reaction between [Fe(eta(5)-C5H5)I(CO)(kappa(1)-dppm ...

2019

Screening-based approach to discover effective platinum-based chemotherapies for cancers with poor prognosis

Paul Joseph Dyson, Gerardo Turcatti, Fabien Kuttler, Damiano Banfi, Hristo Plamenov Varbanov

Drug combinations are extensively used to treat cancer and are often selected according to complementary mechanisms. Here, we describe a cell-based high-throughput screening assay for identification of synergistic combinations between broadly applied plati ...

2019

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance

Filipe Amândio Brandão Sanches Vong Martins, Olivier Michielin

Immune-checkpoint inhibitors (ICIs), including anti-cytotoxic T lymphocyte antigen 4 (CTLA-4), anti-programmed cell death 1 (PD-1) and anti-programmed cell death 1 ligand 1 (PD-L1) antibodies, are arguably the most important development in cancer therapy o ...

NATURE PUBLISHING GROUP2019

Chattez avec Graph Search

Posez n’importe quelle question sur les cours, conférences, exercices, recherches, actualités, etc. de l’EPFL ou essayez les exemples de questions ci-dessous.

AVERTISSEMENT : Le chatbot Graph n'est pas programmé pour fournir des réponses explicites ou catégoriques à vos questions. Il transforme plutôt vos questions en demandes API qui sont distribuées aux différents services informatiques officiellement administrés par l'EPFL. Son but est uniquement de collecter et de recommander des références pertinentes à des contenus que vous pouvez explorer pour vous aider à répondre à vos questions.

Chimiothérapie

Recent Considerations in the Application of RAPTA-C for Cancer Treatment and Perspectives for Its Combination with Immunotherapies

Lymphoma Chemotherapy: Hungry Macrophages Strike the Final Blow

Type I interferon/IRF7 axis instigates chemotherapy-induced immunological dormancy in breast cancer

Versatile Route to trans-Platinum(II) Complexes via Manipulation of a Coordinated 3-(Pyridin-3-yl)propanoicAcid Ligand

Dual-responsive polyphosphazene as a common platform for highly efficient drug self-delivery

RasGRP1 is a potential biomarker for stratifying anti-EGFR therapy response in colorectal cancer

Heterobimetallic Ru(mu-dppm)Fe and homobimetallic Ru(mu-dppm)Ru complexes as potential anti-cancer agents

Anti-angiogenic immunotherapy for lung cancer

Screening-based approach to discover effective platinum-based chemotherapies for cancers with poor prognosis

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance

Graph Chatbot

Chattez avec Graph Search

Recent Considerations in the Application of RAPTA-C for Cancer Treatment and Perspectives for Its Combination with Immunotherapies

Anti-angiogenic immunotherapy for lung cancer

Lymphoma Chemotherapy: Hungry Macrophages Strike the Final Blow

Heterobimetallic Ru(mu-dppm)Fe and homobimetallic Ru(mu-dppm)Ru complexes as potential anti-cancer agents

Type I interferon/IRF7 axis instigates chemotherapy-induced immunological dormancy in breast cancer

RasGRP1 is a potential biomarker for stratifying anti-EGFR therapy response in colorectal cancer

Versatile Route to trans-Platinum(II) Complexes via Manipulation of a Coordinated 3-(Pyridin-3-yl)propanoicAcid Ligand

Dual-responsive polyphosphazene as a common platform for highly efficient drug self-delivery

Screening-based approach to discover effective platinum-based chemotherapies for cancers with poor prognosis

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance